Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Shares Issued (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Shares Issued for 6 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 97.75% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 95.65% decrease, with the full-year FY2025 number at $2.0 million, down 95.65% from a year prior.
  • Shares Issued was $1.0 million for Q4 2025 at GeneDx Holdings, up from -$12.8 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $442.7 million in Q3 2021 to a low of -$441.4 million in Q4 2021.
  • A 5-year average of -$5.0 million and a median of $422000.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 46784.83% in 2022, then crashed 6320.02% in 2023.
  • GeneDx Holdings' Shares Issued stood at -$441.4 million in 2021, then surged by 99.5% to -$2.2 million in 2022, then plummeted by 6320.02% to -$142.7 million in 2023, then skyrocketed by 132.41% to $46.2 million in 2024, then tumbled by 97.75% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Shares Issued are $1.0 million (Q4 2025), -$12.8 million (Q3 2025), and $13.0 million (Q2 2025).